Skip to main content

BNT162b2 Vaccination Linked to Lower Risk for COVID-19 Encounters in Children Under 5

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 15, 2023 -- For children younger than 5 years, receiving two or three doses of the wild-type BNT162b2 vaccine is associated with a reduced risk for COVID-19 encounters in the emergency department or urgent care or in outpatient settings, according to a research letter published online Sept. 15 in the Journal of the American Medical Association.

Sara Y. Tartof, Ph.D., M.P.H., from Kaiser Permanente Southern California in Pasadena, and colleagues estimated the association between receipt of the wild-type BNT162b2 vaccine and medically attended COVID-19 outcomes among children younger than 5 years. Data were included for 24,261 emergency department, urgent care, or outpatient acute respiratory infection encounters (48, 29, and 23 percent, respectively) during the study period.

The researchers found that 10 percent had positive test results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 6 percent were vaccinated. Overall, 3.3 and 6.3 percent of cases and controls (without positive test results for SARS-CoV-2), respectively, were vaccinated with two or three doses of BNT162b2. For children who received two or three doses of BNT162b2, the adjusted odds ratio was 0.70, 0.60, and 0.67 for a COVID-19-related emergency department or urgent care encounter, outpatient visits, and either outcome, respectively. The risk for a positive test result for SARS-CoV-2 during emergency department or urgent care and outpatient encounters among those who received two and three doses was 0.56 and 0.88, respectively.

"Updated vaccines will likely be needed to maintain protection against contemporary omicron strains in young children," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Pfizer, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Further Support and Information on COVID-19

Read this next

COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes

TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...

Cannabis Use Tied to Risk of COVID-19 Hospitalizations, ICU Admissions

TUESDAY, June 25, 2024 -- Current cannabis use may be an independent risk factor for COVID-19–related complications, according to a study published online June 21...

FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine

FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.